EDEN PRAIRIE, Minn., July 25, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients’ lives, today announced that the Company will report financial results for the second quarter 2023 after market close on Monday, August 14, 2023. Company management will host a corresponding conference call beginning at 3:30 pm Central Time / 4:30 pm Eastern Time.
Individuals interested in listening to the conference call may do so by dialing 866-652-5200 for domestic callers or 412-317-6060 for international callers. Please reference Conference ID: 10181369. To listen to a live webcast, please visit the investor relations section of Miromatrix's website at: https://miromatrix.gcs-web.com/
Miromatrix Medical Inc. is a life sciences company pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve patients' lives. The Company has developed a proprietary perfusion technology platform for bioengineering organs that it believes will efficiently scale to address the shortage of available human organs. The Company's initial development focus is on human livers and kidneys. For more information, visit miromatrix.com.